Form 8-K - Current report:
SEC Accession No. 0001558370-20-014003
Filing Date
2020-11-20
Accepted
2020-11-20 07:36:58
Documents
14
Period of Report
2020-11-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20201120x8k.htm   iXBRL 8-K 36184
2 EX-99.1 adap-20201120xex99d1.htm EX-99.1 33847
3 GRAPHIC adap-20201120xex99d1001.jpg GRAPHIC 9131
  Complete submission text file 0001558370-20-014003.txt   210736

Data Files

Seq Description Document Type Size
4 EX-101.SCH adap-20201120.xsd EX-101.SCH 3222
5 EX-101.LAB adap-20201120_lab.xml EX-101.LAB 16120
6 EX-101.PRE adap-20201120_pre.xml EX-101.PRE 10939
7 EXTRACTED XBRL INSTANCE DOCUMENT adap-20201120x8k_htm.xml XML 4970
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 201330477
SIC: 2836 Biological Products, (No Diagnostic Substances)